Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Background: The Centers for Disease Control and Prevention (CDC) reports that 42% of adults in the United States (US) are obese, and 10% are severely obese. Obesity has many known associated health risks, and successful treatment decreases those risks. Management always includes diet and lifestyle...
Saved in:
Main Authors: | Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser |
---|---|
Format: | Article |
Language: | English |
Published: |
The University of Toledo
2025-02-01
|
Series: | Translation |
Subjects: | |
Online Access: | https://openjournals.utoledo.edu/index.php/translation/article/view/1218 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01) -
GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01) -
Current treatment landscape for obesity in Singapore
by: Phong Ching Lee, et al.
Published: (2023-03-01) -
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01) -
Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
by: Elisa Dinoi, et al.
Published: (2025-02-01)